References
[1] Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010; 70:447-52. doi: 10.1158/0008-5472.CAN-09-3783.
[2] Vannucchi AM, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev. 2009; 18:2068-73.
doi: 10.1158/1055-9965.EPI-09-0353.
[3] Brunner AM, Hobbs G, Jalbut MM, et al. A population-basedanalysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. LeukLymphoma. 2016; 57:1197-200.
doi: 10.3109/10428194.2015.1071490.
[4] Brabrand M, Frederiksen H. Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications. Cancers (Basel). 2020; 12:3061. doi: 10.3390/cancers12103061.
[5] Zhang Y, Han Y, Teng G, et al. Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms. Cancer Med. 2023 Feb 2. doi: 10.1002/cam4.5666.
[6] Marchetti M, Ghirardi A, Masciulli A, et al. Second cancers in MPN: Survival analysis from an international study. Am J He-matol. 2020; 95:295-301. doi: 10.1002/ajh.25700.
[7] Barbui T, Ghirardi A, Masciulli A, et al. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia. 2019; 33:1996-2005. doi: 10.1038/s41375-019-0487-8.
[8] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127:2391-2405. doi: 10.1182/blood-2016-06-721662. PMID: 31659364.
[9] Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sørensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danishpopulation-based cohort study. Blood. 2011; 118:6515-20.
doi: 10.1182/blood-2011-04-348755.
[10] Gavini DR, Salvi DJ, Shah PH, Uma D, Lee JH, Hamid P. Non-melanoma Skin Cancers in Patients on Hydroxyurea for Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review. Cureus. 2021; 13:e16978.
doi: 10.7759/cureus.16978.
[11] Kissova J, Ovesna P, Penka M, Bulikova A, Kiss I. Second malignancies in philadelphia-negative myeloproliferative neoplasms-single-center experience. Anticancer Res. 2014; 34:2489-96.
[12] Maffioli M, Giorgino T, Mora B, et al. Second primarymalignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. Blood Adv. 2019; 3:3196-3200. doi: 10.1182/bloodadvances.2019000646.
[13] Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-celllymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018; 132:694-706. doi: 10.1182/blood-2017-10-810739.
[14] Rumi E, Zibellini S, Boveri E, et al. Ruxolitinib treatment and risk of B-celllymphomas in myeloproliferative neoplasms. Am J Hematol. 2019; 94:E185-E188. doi: 10.1002/ajh.25489.
[15] Pemmaraju N, Kantarjian H, Nastoupil L, et al. Characteristics of patients with myeloproliferative neoplasms with lymphoma, withorwithout JAK inhibitor therapy. Blood. 2019; 133:2348-2351. doi: 10.1182/blood-2019-01-897637.
[16] Cumbo C, Anelli L, Zagaria A, et al. Second CancerOnset in MyeloproliferativeNeoplasms: What, When, Why? Int J MolSci. 2022; 23:3177. doi:10.3390/ijms23063177.
[17] De Stefano V, Ghirardi A, Masciulli A, et al. Arterialthrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. Blood. 2020; 135:381-386. doi: 10.1182/blood.2019002614.